| Q38648131 | A Computational Investigation of Small-Molecule Engagement of Hot Spots at Protein-Protein Interaction Interfaces. |
| Q40105822 | A cleavage-resistant urokinase plasminogen activator receptor exhibits dysregulated cell-surface clearance |
| Q39999171 | A composite role of vitronectin and urokinase in the modulation of cell morphology upon expression of the urokinase receptor |
| Q80027715 | A direct link between expression of urokinase plasminogen activator receptor, growth rate and oncogenic transformation in mouse embryonic fibroblasts |
| Q36298409 | A flexible multidomain structure drives the function of the urokinase-type plasminogen activator receptor (uPAR) |
| Q35559411 | A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction |
| Q37695404 | A novel tumor targeting drug carrier for optical imaging and therapy |
| Q40302526 | A region in urokinase plasminogen receptor domain III controlling a functional association with alpha5beta1 integrin and tumor growth |
| Q43264829 | Accelerated thrombus lysis in the blood of plasminogen activator inhibitor deficient mice is inhibited by PAI-1 with a very long half-life |
| Q52768529 | Acute effects of moderate altitude on biomarkers of cardiovascular inflammation and endothelial function and their differential modulation by dual endothelin receptor blockade. |
| Q39574481 | Assessing the performance of the MM/PBSA and MM/GBSA methods. 6. Capability to predict protein-protein binding free energies and re-rank binding poses generated by protein-protein docking |
| Q89736584 | Be Active or Not: the Relative Contribution of Active and Passive Tumor Targeting of Nanomaterials |
| Q38669149 | Biophysical Mechanisms Mediating Fibrin Fiber Lysis. |
| Q44256854 | Cardiovascular Disease Biomarkers and suPAR in Predicting Decline in Renal Function: A Prospective Cohort Study. |
| Q41908264 | Challenges for drug discovery - a case study of urokinase receptor inhibition |
| Q83282038 | Characterization of the functional epitope on the urokinase receptor. Complete alanine scanning mutagenesis supplemented by chemical cross-linking |
| Q35312973 | Conformational regulation of urokinase receptor function: impact of receptor occupancy and epitope-mapped monoclonal antibodies on lamellipodia induction. |
| Q45106348 | Conserved structural determinants in three-fingered protein domains |
| Q90092778 | Crystal Structures of Human C4.4A Reveal the Unique Association of Ly6/uPAR/α-neurotoxin Domain |
| Q27650194 | Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes |
| Q52709764 | Current advances in circulating inflammatory biomarkers in atherosclerosis and related cardio-cerebrovascular diseases. |
| Q37203518 | DOT corrected fluorescence molecular tomography using targeted contrast agents for small animal tumor imaging |
| Q62813888 | Diagnostic Value of Soluble Urokinase-Type Plasminogen Activator Receptor in Addition to High-Sensitivity Troponin I in Early Diagnosis of Acute Myocardial Infarction. |
| Q92510521 | Did evolution create a flexible ligand-binding cavity in the urokinase receptor through deletion of a plesiotypic disulfide bond? |
| Q37093692 | Domain 2 of uPAR regulates single-chain urokinase-mediated angiogenesis through β1-integrin and VEGFR2 |
| Q36010344 | Dual actions of albumin packaging and tumor targeting enhance the antitumor efficacy and reduce the cardiotoxicity of doxorubicin in vivo |
| Q44008835 | Effect of surface charge and ligand organization on the specific cell-uptake of uPAR-targeted nanoparticles |
| Q38245545 | Effects of allopurinol on exercise-induced muscle damage: new therapeutic approaches? |
| Q83822363 | Elevated soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in Staphylococcus aureus bacteremia |
| Q24336025 | Epileptic and developmental disorders of the speech cortex: ligand/receptor interaction of wild-type and mutant SRPX2 with the plasminogen activator receptor uPAR |
| Q35440794 | Expression of C4.4A, a structural uPAR homolog, reflects squamous epithelial differentiation in the adult mouse and during embryogenesis |
| Q35151053 | Expression of uPAR in tumor-associated stromal cells is associated with colorectal cancer patient prognosis: a TMA study |
| Q27681464 | Identification of a New Epitope in uPAR as a Target for the Cancer Therapeutic Monoclonal Antibody ATN-658, a Structural Homolog of the uPAR Binding Integrin CD11b (αM) |
| Q38111811 | Impact of expression of the uPA system in sarcomas |
| Q57563925 | Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation |
| Q38912052 | Inhibitory serpins. New insights into their folding, polymerization, regulation and clearance |
| Q38297320 | Lanthanide-doped luminescent nano-bioprobes for the detection of tumor markers. |
| Q39506373 | Lanthanide-doped luminescent nano-bioprobes: from fundamentals to biodetection. |
| Q37095640 | Lanthanides: Applications in Cancer Diagnosis and Therapy |
| Q41856837 | Leach-proof magnetic thrombolytic nanoparticles and coatings of enhanced activity |
| Q90093902 | Levels of Soluble Urokinase Plasminogen Activator Receptor in Pediatric Lower Respiratory Tract Infections |
| Q34466969 | Ligand binding alters dimerization and sequestering of urokinase receptors in raft-mimicking lipid mixtures |
| Q33278178 | Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region |
| Q30380709 | Mapping the topographic epitope landscape on the urokinase plasminogen activator receptor (uPAR) by surface plasmon resonance and X-ray crystallography |
| Q47726693 | Mimicking Intermolecular Interactions of Tight Protein-Protein Complexes for Small-Molecule Antagonists. |
| Q35604600 | Mimicry of the regulatory role of urokinase in lamellipodia formation by introduction of a non-native interdomain disulfide bond in its receptor. |
| Q48165741 | Multibiomarker analysis in patients with acute myocardial infarction |
| Q38870726 | Multifunctional Nano-Bioprobes Based on Rattle-Structured Upconverting Luminescent Nanoparticles. |
| Q27652688 | NMR Solution Structure of the Neurotrypsin Kringle Domain † ‡ |
| Q64245273 | Nanoparticle Binding to Urokinase Receptor on Cancer Cell Surface Triggers Nanoparticle Disintegration and Cargo Release |
| Q90662820 | Novel Biomarkers in Patients with Chronic Kidney Disease: An Analysis of Patients Enrolled in the GCKD-Study |
| Q45927197 | Orientation-controlled conjugation of haloalkane dehalogenase fused homing peptides to multifunctional nanoparticles for the specific recognition of cancer cells. |
| Q61446738 | Origin and diversification of the plasminogen activation system among chordates |
| Q39679559 | Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo |
| Q34430691 | Pericellular proteolysis in cancer |
| Q93117519 | Predictive value of soluble urokinase-type plasminogen activator receptor for mortality in patients with suspected myocardial infarction |
| Q38164339 | Primary focal and segmental glomerulosclerosis and soluble factor urokinase-type plasminogen activator receptor |
| Q24299743 | Pro-urokinase-type plasminogen activator is a substrate for hepsin |
| Q33758094 | Probing binding and cellular activity of pyrrolidinone and piperidinone small molecules targeting the urokinase receptor |
| Q92256627 | Profile of Matrix-Remodeling Proteinases in Osteoarthritis: Impact of Fibronectin |
| Q33795055 | Proteases Revisited: Roles and Therapeutic Implications in Fibrosis |
| Q35560686 | Proteases involved in cartilage matrix degradation in osteoarthritis. |
| Q37783622 | Radiometallated Peptides Targeting Guanylate Cyclase C and the Urokinase-Type Plasminogen Activator Receptor |
| Q37660895 | Regulation of cell signalling by uPAR. |
| Q33683537 | Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas. |
| Q36997616 | Role of urokinase receptor in tumor progression and development |
| Q33743804 | SLEEPLESS, a Ly-6/neurotoxin family member, regulates the levels, localization and activity of Shaker |
| Q30496585 | Selective abrogation of the uPA-uPAR interaction in vivo reveals a novel role in suppression of fibrin-associated inflammation |
| Q34370103 | Serum-stable RNA aptamers to urokinase-type plasminogen activator blocking receptor binding. |
| Q89846943 | Sex Differences in Circulating Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels and Adverse Outcomes in Coronary Artery Disease |
| Q36549551 | Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models |
| Q36276812 | Small Molecules Engage Hot Spots through Cooperative Binding To Inhibit a Tight Protein-Protein Interaction |
| Q101238345 | Small-Molecule Inhibition of the uPAR•uPA Interaction by Conformational Selection |
| Q34587758 | Small-molecule inhibition of the uPAR·uPA interaction: synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis |
| Q45306072 | Soluble Urokinase Plasminogen Activator Receptor and the Risk of Coronary Artery Disease in Young Chinese Patients. |
| Q46281060 | Soluble Urokinase Plasminogen Activator Receptor: A New Biomarker in the Pediatric Intensive Care Unit |
| Q99608131 | Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI |
| Q36429637 | Soluble Urokinase Receptor and Chronic Kidney Disease. |
| Q33741426 | Soluble Urokinase Receptor and the Kidney Response in Diabetes Mellitus. |
| Q40261498 | Soluble urokinase plasminogen activator receptor and hypertension among black South Africans after 5 years |
| Q92277771 | Structural Biology and Protein Engineering of Thrombolytics |
| Q47098588 | Structural Principles in the Development of Cyclic Peptidic Enzyme Inhibitors |
| Q27650677 | Structural basis for EGFR ligand sequestration by Argos |
| Q36237711 | Structural basis of interaction between urokinase-type plasminogen activator and its receptor |
| Q27659603 | Structure-based Engineering of Species Selectivity in the Interaction between Urokinase and Its Receptor: IMPLICATION FOR PRECLINICAL CANCER THERAPY |
| Q38120755 | Structure-driven design of radionuclide tracers for non-invasive imaging of uPAR and targeted radiotherapy. The tale of a synthetic peptide antagonist |
| Q92757292 | Structure-function relationship of an Urokinase Receptor-derived peptide which inhibits the Formyl Peptide Receptor type 1 activity |
| Q39154565 | Sub-10 nm lanthanide-doped CaF2 nanoprobes for time-resolved luminescent biodetection. |
| Q33912826 | Synthesis and characterization of an (111)In-labeled peptide for the in vivo localization of human cancers expressing the urokinase-type plasminogen activator receptor (uPAR) |
| Q34555267 | Targeting NF-κB in infantile hemangioma-derived stem cells reduces VEGF-A expression. |
| Q35563311 | Targeting multiple conformations leads to small molecule inhibitors of the uPAR·uPA protein-protein interaction that block cancer cell invasion |
| Q47140492 | Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells. |
| Q30393215 | Targeting therapeutics across the blood brain barrier (BBB), prerequisite towards thrombolytic therapy for cerebrovascular disorders-an overview and advancements |
| Q36442395 | The High Affinity Binding Site on Plasminogen Activator Inhibitor-1 (PAI-1) for the Low Density Lipoprotein Receptor-related Protein (LRP1) Is Composed of Four Basic Residues |
| Q47638043 | The Neurobiological Basis of Sleep: Insights from Drosophila |
| Q36805290 | The inhibitory effect of HKa in endothelial cell tube formation is mediated by disrupting the uPA-uPAR complex and inhibiting its signaling and internalization |
| Q36997621 | The many spaces of uPAR: delivery of theranostic agents and nanobins to multiple tumor compartments through a single target |
| Q37285095 | The urokinase plasminogen activator receptor promotes efferocytosis of apoptotic cells. |
| Q37255861 | The urokinase receptor homolog Haldisin is a novel differentiation marker of stratum granulosum in squamous epithelia. |
| Q37688084 | The urokinase receptor-derived cyclic peptide [SRSRY] suppresses neovascularization and intravasation of osteosarcoma and chondrosarcoma cells. |
| Q90171163 | Therapeutics targeting the fibrinolytic system |
| Q89537067 | Tumor Targeting Chemo- and Photodynamic Therapy Packaged in Albumin for Enhanced Anti-Tumor Efficacy |
| Q40058871 | Type II transmembrane serine proteases as potential target for anti-influenza drug discovery |
| Q38685434 | Unwinding focal segmental glomerulosclerosis |
| Q34100895 | Urokinase receptor promotes ovarian cancer cell dissemination through its 84-95 sequence. |
| Q26865306 | Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications |
| Q46470855 | Urokinase-type plasminogen activator receptor induces conformational changes in the integrin alphaMbeta2 headpiece and reorientation of its transmembrane domains |
| Q36201781 | Urokinase-type plasminogen activator-like proteases in teleosts lack genuine receptor-binding epidermal growth factor-like domains. |
| Q27644652 | X-ray sequence and crystal structure of luffaculin 1, a novel type 1 ribosome-inactivating protein |
| Q28582042 | siRNA against plasminogen activator inhibitor-1 ameliorates bleomycin-induced lung fibrosis in rats |
| Q30444144 | uPAR-induced cell adhesion and migration: vitronectin provides the key |